Amarin's Vascepa granted priority review status from Health Canada

Apr. 01, 2019 8:21 AM ETAmarin Corporation plc (AMRN)HLTRF, HLS:CABy: Mamta Mayani, SA News Editor19 Comments
  • Health Canada grants priority review status for Amarin's (NASDAQ:AMRN) licensee, HLS Therapeutics' (OTCPK:HLTRF) New Drug Submission (“NDS”) for Vascepa (icosapent ethyl) capsules.
  • HLS Therapeutics anticipates filing the NDS in April, seeking approval to market and sell Vascepa in Canada to reduce the risk of ischemic cardiovascular events in statin-treated patients with elevated triglycerides and other risk factors.
  • Priority review shortens the review the review period to 215 calendar days versus 355 days for a standard review.
  • AMRN shares are up 1% premarket.

Recommended For You

Comments (19)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.